세계 원료의약품 CDMO 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장 및 동향 예측(2024-2032년)

The global demand for Active Pharmaceutical Ingredient CDMO Market is presumed to reach the market size of nearly USD 207.24 Billion by 2032 from USD 102.3 Billion in 2023 with a CAGR of 8.16% under the study period 2024 - 2032.

Active Pharmaceutical Ingredient Contract Development and Manufacturing Organizations (API CDMOs) specialize in the development and production of active pharmaceutical ingredients, which are the biologically active components in medications. These organizations offer services ranging from research and development to large-scale manufacturing, providing pharmaceutical companies with the expertise and infrastructure to bring drugs to market efficiently and in compliance with regulatory standards.

MARKET DYNAMICS

The Active Pharmaceutical Ingredient (API) Contract Development and Manufacturing Organization market is driven by factors such as the increasing complexity of drug development, outsourcing trends in the pharmaceutical industry, and the demand for cost-effective and flexible manufacturing solutions. Pharmaceutical companies are turning to API CDMOs to leverage their expertise in developing and producing high-quality active pharmaceutical ingredients. The rising number of biopharmaceuticals and specialty drugs, coupled with the need for specialized manufacturing capabilities, contributes to the market's growth. API CDMOs offer benefits such as reduced time-to-market, access to advanced technologies, and risk mitigation in drug development. The trend towards personalized medicine and the growing pipeline of innovative therapies also boost the demand for API CDMO services. Regulatory requirements and the need for compliance with Good Manufacturing Practice (GMP) standards drive pharmaceutical companies to partner with specialized API CDMOs, fostering innovation and efficiency in drug development.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of active pharmaceutical ingredient cdmo. The growth and trends of active pharmaceutical ingredient cdmo industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the active pharmaceutical ingredient cdmo market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

• Traditional Active Pharmaceutical Ingredient (Traditional Api)
• Highly Potent Active Pharmaceutical Ingredient (Hp-Api)
• Antibody Drug Conjugate (Adc)
• Others

By Synthesis

• Synthetic
• Biotech

By Drug

• Innovative
• Generics

By Workflow

• Clinical
• Commercial

By Application

• Oncology
• Hormonal
• Glaucoma
• Cardiovascular Disease
• Diabetes
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Active Pharmaceutical Ingredient CDMO market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Active Pharmaceutical Ingredient CDMO market include Cambrex Corporation, Recipharm AB, Thermo Fisher Scientific Inc. (Pantheon), CordenPharma International, Samsung Biologics, Lonza, Catalent, Inc., Siegfried Holding AG, Piramal Pharma Solutions, Boehringer Ingelheim International GmbH. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . ACTIVE PHARMACEUTICAL INGREDIENT CDMO - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product
  • 3.7.2 Market Attractiveness Analysis By Synthesis
  • 3.7.3 Market Attractiveness Analysis By Drug
  • 3.7.4 Market Attractiveness Analysis By Workflow
  • 3.7.5 Market Attractiveness Analysis By Application
  • 3.7.6 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET ANALYSIS BY PRODUCT

• 5.1 Overview by Product
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Product
• 5.4 Traditional Active Pharmaceutical Ingredient (Traditional API) Historic and Forecast Sales by Regions
• 5.5 Highly Potent Active Pharmaceutical Ingredient (HP-API) Historic and Forecast Sales by Regions
• 5.6 Antibody Drug Conjugate (ADC) Historic and Forecast Sales by Regions
• 5.7 Others Historic and Forecast Sales by Regions

6 . GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET ANALYSIS BY SYNTHESIS

• 6.1 Overview by Synthesis
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Synthesis
• 6.4 Synthetic Historic and Forecast Sales by Regions
• 6.5 Biotech Historic and Forecast Sales by Regions

7 . GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET ANALYSIS BY DRUG

• 7.1 Overview by Drug
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Drug
• 7.4 Innovative Historic and Forecast Sales by Regions
• 7.5 Generics Historic and Forecast Sales by Regions

8 . GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET ANALYSIS BY WORKFLOW

• 8.1 Overview by Workflow
• 8.2 Historical and Forecast Data
• 8.3 Analysis by Workflow
• 8.4 Clinical Historic and Forecast Sales by Regions
• 8.5 Commercial Historic and Forecast Sales by Regions

9 . GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET ANALYSIS BY APPLICATION

• 9.1 Overview by Application
• 9.2 Historical and Forecast Data
• 9.3 Analysis by Application
• 9.4 Oncology Historic and Forecast Sales by Regions
• 9.5 Hormonal Historic and Forecast Sales by Regions
• 9.6 Glaucoma Historic and Forecast Sales by Regions
• 9.7 Cardiovascular disease Historic and Forecast Sales by Regions
• 9.8 Diabetes Historic and Forecast Sales by Regions
• 9.9 Others Historic and Forecast Sales by Regions

10 . GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET ANALYSIS BY GEOGRAPHY

• 10.1. Regional Outlook
• 10.2. Introduction
• 10.3. North America Sales Analysis
  • 10.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 10.3.2. North America By Segment Sales Analysis
  • 10.3.3. North America By Country Sales Analysis
  • 10.3.4. United State Sales Analysis
  • 10.3.5. Canada Sales Analysis
  • 10.3.6. Mexico Sales Analysis
• 10.4. Europe Sales Analysis
  • 10.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 10.4.2. Europe by Segment Sales Analysis
  • 10.4.3. Europe by Country Sales Analysis
  • 10.4.4. United Kingdom Sales Analysis
  • 10.4.5. France Sales Analysis
  • 10.4.6. Germany Sales Analysis
  • 10.4.7. Italy Sales Analysis
  • 10.4.8. Russia Sales Analysis
  • 10.4.9. Rest Of Europe Sales Analysis
• 10.5. Asia Pacific Sales Analysis
  • 10.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 10.5.2. Asia Pacific by Segment Sales Analysis
  • 10.5.3. Asia Pacific by Country Sales Analysis
  • 10.5.4. China Sales Analysis
  • 10.5.5. India Sales Analysis
  • 10.5.6. Japan Sales Analysis
  • 10.5.7. South Korea Sales Analysis
  • 10.5.8. Australia Sales Analysis
  • 10.5.9. South East Asia Sales Analysis
  • 10.5.10. Rest Of Asia Pacific Sales Analysis
• 10.6. Latin America Sales Analysis
  • 10.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 10.6.2. Latin America by Segment Sales Analysis
  • 10.6.3. Latin America by Country Sales Analysis
  • 10.6.4. Brazil Sales Analysis
  • 10.6.5. Argentina Sales Analysis
  • 10.6.6. Peru Sales Analysis
  • 10.6.7. Chile Sales Analysis
  • 10.6.8. Rest of Latin America Sales Analysis
• 10.7. Middle East & Africa Sales Analysis
  • 10.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 10.7.2. Middle East & Africa by Segment Sales Analysis
  • 10.7.3. Middle East & Africa by Country Sales Analysis
  • 10.7.4. Saudi Arabia Sales Analysis
  • 10.7.5. UAE Sales Analysis
  • 10.7.6. Israel Sales Analysis
  • 10.7.7. South Africa Sales Analysis
  • 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE ACTIVE PHARMACEUTICAL INGREDIENT CDMO COMPANIES

• 11.1. Active Pharmaceutical Ingredient Cdmo Market Competition
• 11.2. Partnership/Collaboration/Agreement
• 11.3. Merger And Acquisitions
• 11.4. New Product Launch
• 11.5. Other Developments

12 . COMPANY PROFILES OF ACTIVE PHARMACEUTICAL INGREDIENT CDMO INDUSTRY

• 12.1. Company Share Analysis
• 12.2. Market Concentration Rate
• 12.3. Cambrex Corporation
  • 12.3.1. Company Overview
  • 12.3.2. Company Revenue
  • 12.3.3. Products
  • 12.3.4. Recent Developments
• 12.4. Recipharm AB
  • 12.4.1. Company Overview
  • 12.4.2. Company Revenue
  • 12.4.3. Products
  • 12.4.4. Recent Developments
• 12.5. Thermo Fisher Scientific Inc. (Pantheon)
  • 12.5.1. Company Overview
  • 12.5.2. Company Revenue
  • 12.5.3. Products
  • 12.5.4. Recent Developments
• 12.6. CordenPharma International
  • 12.6.1. Company Overview
  • 12.6.2. Company Revenue
  • 12.6.3. Products
  • 12.6.4. Recent Developments
• 12.7. Samsung Biologics
  • 12.7.1. Company Overview
  • 12.7.2. Company Revenue
  • 12.7.3. Products
  • 12.7.4. Recent Developments
• 12.8. Lonza
  • 12.8.1. Company Overview
  • 12.8.2. Company Revenue
  • 12.8.3. Products
  • 12.8.4. Recent Developments
• 12.9. Catalent Inc.
  • 12.9.1. Company Overview
  • 12.9.2. Company Revenue
  • 12.9.3. Products
  • 12.9.4. Recent Developments
• 12.10. Siegfried Holding AG
  • 12.10.1. Company Overview
  • 12.10.2. Company Revenue
  • 12.10.3. Products
  • 12.10.4. Recent Developments
• 12.11. Piramal Pharma Solutions
  • 12.11.1. Company Overview
  • 12.11.2. Company Revenue
  • 12.11.3. Products
  • 12.11.4. Recent Developments
• 12.12. Boehringer Ingelheim International GmbH
  • 12.12.1. Company Overview
  • 12.12.2. Company Revenue
  • 12.12.3. Products
  • 12.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies